XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
V
V

Vertex

News

Reuters - 1 week ago

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.
N
P
V
Reuters - 1 week ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 1 week ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 1 week ago

Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

BRIEF-Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia Vertex Pharmaceuticals Inc VRTX.O : HEALTH CANADA GRANTS MARKETING AUTHORIZATION OF FIRST CRISPR/CAS9 GENE-EDITED THERAPY, CASGEVY® (E
V
Reuters - 2 weeks ago

Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch

UPDATE 2-Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch Adds CEO statement in paragraph 5, background throughout Sept 24 (Reuters) - Bluebird bio BLUE.O will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a second major restructuring in two years as the company focuses on launching its treatments amid a cash crunch.
V
Reuters - 4 weeks ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Dollar Tree Inc DLTR.OQ +7.2% Tesla Inc TSLA.OQ +4.3% Zscaler Inc ZS.OQ +3.1% Comcast Corp CMCSA.OQ +2.7% Amazon.com Inc AMZN.OQ +2.3% Bottom Performers Percent Change Copart Inc CPRT.OQ -6.6% Old Dominion Freight Line Inc ODFL.OQ -5.4% AstraZeneca PLC AZN.OQ -3.4% Super Micro Computer Inc SMCI.OQ -3.1% Vertex Pharmaceuticals Inc VRTX.OQ -2.6% The Nasdaq 100 .NDX lost 36.77 points
A
A
C
T
V
D
U
C
O
Reuters - 4 weeks ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +3.2% Dollar Tree Inc DLTR.OQ +2.3% Amazon.com Inc AMZN.OQ +2.1% Comcast Corp CMCSA.OQ +1.6% Arm Holdings PLC ARM.OQ +1.2% Bottom Performers Percent Change Copart Inc CPRT.OQ -7.1% Old Dominion Freight Line Inc ODFL.OQ -6.8% AstraZeneca PLC AZN.OQ -3.5% Vertex Pharmaceuticals Inc VRTX.OQ -3.1% Regeneron Pharmaceuticals Inc REGN.OQ -3.0% The Nasdaq 100 .NDX lost 9
A
A
C
R
T
V
D
U
C
O
Reuters - 1 month ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O
Reuters - 2 months ago

Financial Times - Aug 8

PRESS DIGEST- Financial Times - Aug 8 Aug 8 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - NHS in England to roll out 1.7 mln pound Crispr gene editing drug - Ministry of Defence asks suppliers to identify budget cuts - H2O Asset Management to pay investors 250 mln euros after FCA finds 'serious breaches' - UK signals move to curb overseas hiring for tech and engineering jobs Overview
V
Reuters - 2 months ago

British Business - August 8

PRESS DIGEST-British Business - August 8 Aug 8 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - Asset manager H2O has agreed to pay out 250 million euros ($273.35 million) to investors who have been trapped since 2020 in illiquid funds linked to Lars Windhorst, the German financier.
G
V
Reuters - 2 months ago

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UPDATE 1-UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Updates with details from statement in paragraphs 2-6, updates with background in paragraphs 7-8 Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday.
V
Reuters - 2 months ago

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UPDATE 1-UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Updates with details from statement in paragraphs 2-6, updates with background in paragraphs 7-8 Aug 7 (Reuters) - Britain's National Health Service (NHS) will begin to roll out a gene therapy from Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics CRSP.BN to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday.
V
Reuters - 2 months ago

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder

UK's NHS to roll out Vertex/CRISPR gene therapy for rare blood disorder Aug 7 (Reuters) - Britain's National Health Service(NHS) will begin rolling out Vertex Pharmaceuticals VRTX.O and CRISPR Therapeutics' CRSP.BN gene therapy to treat rare blood disorder beta thalassemia, Vertex said in a statement on Wednesday. Reporting by Gursimran Kaur in Ben
V
Reuters - 2 months ago

Vertex Announces Casgevy Reimbursement Agreement For Treatment Of Transfusion-Dependent Beta Thalassemia In England

BRIEF-Vertex Announces Casgevy Reimbursement Agreement For Treatment Of Transfusion-Dependent Beta Thalassemia In England Aug 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O : VERTEX ANNOUNCES CASGEVY™ REIMBURSEMENT AGREEMENT FOR THE TREATMENT OF TRANSFUSION-DEPENDENT BETA THALASSEMIA IN ENGLAND VERTEX PHARMACEUTICALS - ELIGIBLE TRANSFUSION-DEPEN
V
Reuters - 2 months ago

US FDA approves Novartis' kidney disease drug

UPDATE 2-US FDA approves Novartis' kidney disease drug Adds background in paragraphs 6 to 10 By Sriparna Roy Aug 7 (Reuters) - The U.S. Food and Drug Administration has approved the use of Novartis' NOVN.S drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's website showed on Wednesday. The drug, Fabhalta, is already approved to treat adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder.
N
V
Reuters - 2 months ago

U.S. Booking Holdings, Doordash, Vertex Pharmaceuticals

U.S. RESEARCH ROUNDUP- Booking Holdings, Doordash, Vertex Pharmaceuticals Aug 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Booking Holdings, Doordash and Vertex Pharmaceuticals, on Monday. HIGHLIGHTS * Academy Sports and Outdoors Inc ASO.O : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Jefferies cuts target price to $4350 from $4650 * Doordash DASH.O : D.A.
A
B
C
C
C
C
E
V
E
A
B
C
C
C
C
Reuters - 2 months ago

US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says

UPDATE 1-US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says Updates with details on Vertex Pharmaceuticals By Caroline Valetkevitch NEW YORK, Aug 2 (Reuters) - The earnings growth estimate for S&P 500 .SPX companies for the second quarter dipped to 12.9% as of Friday from 13.3% on Thursday, according to LSEG data. The latest estimate is based on actual results from 376 of the S&P 500 companies and estimates for the rest.
V
U
Reuters - 2 months ago

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments Aug 1 (Reuters) - Vertex Pharmaceuticals VRTX.O raised its annual revenue forecast on Thursday, betting on robust demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue in the range of $10.65 to $10.85 billion, compared to its prior forecast of $10.55 to $10.75 billion.
V
Reuters - 2 months ago

Vertex Pharmaceuticals Q2 Net Income 3,593.6 Million

BRIEF-Vertex Pharmaceuticals Q2 Net Income USD -3,593.6 Million Aug 01 (Reuters) - Vertex Pharmaceuticals Q2 revenue USD 2,645.6 million vs. IBES estimate USD 2,662 million. Q2 adjusted operating income USD -3,514.7 million vs. IBES estimate USD 1,243 million Q2 pretax profit USD -3,391.2 million vs. IBES estimate USD 1,345 million Q2 adjusted net income USD -3,593.6 million vs.
V
Reuters - 2 months ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Meta Platforms Inc META.OQ +6.1% Dexcom Inc DXCM.OQ +3.5% Cognizant Technology Solutions Corp CTSH.OQ +2.8% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% AstraZeneca PLC AZN.OQ +1.4% Bottom Performers Percent Change Moderna Inc MRNA.OQ -19.5% Arm Holdings PLC ARM.OQ -16.0% Qualcomm Inc QCOM.OQ -8.7% Lam Research Corp LRCX.OQ -8.3% Micron Technology Inc MU.OQ -6.7% The Nasdaq 100 .NDX l
A
C
M
Q
V
L
U
D

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.